MedPath

Tideglusib: Expanded Access Use in Congenital Myotonic Dystrophy

Conditions
Congenital Myotonic Dystrophy
Registration Number
NCT07119775
Lead Sponsor
AMO Pharma Limited
Brief Summary

This treatment plan is limited to a single patient with Congenital Myotonic Dystrophy, who is ineligible or otherwise unable to participate in ongoing clinical trials.

Detailed Description

Not available

Recruitment & Eligibility

Status
AVAILABLE
Sex
Not specified
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
EXPANDED_ACCESS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.